{"title": "First experimental evaluation of pharmaceutical industry-led access program", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "First experimental evaluation of pharmaceutical industry-led access program"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/03/190305153651.htm"}], "link": "https://www.sciencedaily.com/releases/2019/03/190305153651.htm", "summary": "A new study is the first to use a randomized trial design to generate rigorous evidence on the impact of a pharmaceutical industry-led medicines access program.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "A new study is the first to use a randomized trial design to generate rigorous evidence on the impact of a pharmaceutical industry-led medicines access program."}, "published": "Tue, 05 Mar 2019 15:36:51 EST", "published_parsed": [2019, 3, 5, 20, 36, 51, 1, 64, 0], "id": "https://www.sciencedaily.com/releases/2019/03/190305153651.htm", "guidislink": false}